Combination drug approach aims to tackle tough childhood cancer

NCT ID NCT04299113

Ongoing Disease control Sponsor: Jonsson Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This early-phase trial tests a combination of two drugs—mocetinostat and vinorelbine—in children, adolescents, and young adults with rhabdomyosarcoma that has spread, cannot be surgically removed, or has returned after treatment. Mocetinostat works by blocking enzymes that help cancer cells grow, while vinorelbine is a chemotherapy drug that stops cancer cells from dividing. The study aims to find the safest and most effective dose of this combination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mocetinostat and vinorelbine
What this could lead to: If successful, this combination could offer a new treatment option for children and young adults with rhabdomyosarcoma that has not responded to standard therapy.
What could go wrong: This is an early-phase trial with a small number of participants, so the benefits and risks are not yet well understood. The combination may cause significant side effects or may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHABDOMYOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rhabdomyosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHABDOMYOSARCOMA

Contacts and locations

Show contact details

Locations

Rebecca Phelan

Los Angeles, California, 90095, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.